Compare DOLE & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOLE | NNNN |
|---|---|---|
| Founded | 1851 | 2021 |
| Country | Ireland | Germany |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2021 | N/A |
| Metric | DOLE | NNNN |
|---|---|---|
| Price | $15.68 | $26.89 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | ★ 586.8K | 18.1K |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $9,172,907,000.00 | N/A |
| Revenue This Year | $4.54 | N/A |
| Revenue Next Year | $1.83 | N/A |
| P/E Ratio | ★ $29.34 | $446.57 |
| Revenue Growth | ★ 8.23 | N/A |
| 52 Week Low | $12.52 | $6.02 |
| 52 Week High | $16.51 | $55.65 |
| Indicator | DOLE | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 65.90 | 61.21 |
| Support Level | $15.60 | $26.48 |
| Resistance Level | $15.73 | $30.70 |
| Average True Range (ATR) | 0.36 | 2.07 |
| MACD | 0.18 | 0.48 |
| Stochastic Oscillator | 96.81 | 86.64 |
Dole PLC operates in the North American and European markets for fresh fruits and vegetables. The company's segment includes Fresh Fruit; Diversified Fresh Produce - EMEA; Diversified Fresh Produce - Americas and ROW. It generates maximum revenue from the Diversified Fresh Produce - EMEA segment. Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European, and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace. Geographically, the company operates in United States, Ireland, U.K. Spain, Sweden, and Others.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.